For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 5,106,949 | 12,544,223.5* | 3,161,064 | 2,565,982 |
| Acquired in-process research and development expense | 10,426,257 | - | - | - |
| General and administrative | 2,221,823 | 1,188,131* | 1,400,136 | 1,655,152 |
| Acquisition-related transaction costs | - | 2,451,424.75* | - | - |
| Total general and administrative | - | 3,639,555.75* | - | - |
| Total operating expenses | 17,755,029 | 16,183,779.25 | 4,561,200 | 4,221,134 |
| Operating loss | -17,755,029 | -16,183,779.25* | -4,561,200 | -4,221,134 |
| Change in fair value of warrant liabilities | 125,348 | 7,436,948.5* | 279,161 | 161,714 |
| Change in fair value of contingent consideration | -116,000 | -396,000* | - | - |
| Grant income | 139,835 | 1,014,078.5* | 22,174 | 153,685 |
| Currency exchange loss (gain) | -21,108 | 7,242* | -32,051 | -47,487 |
| Interest income | 91,888 | 78,755.5* | 147 | 148 |
| Interest expense | - | -11,264* | 5,960 | - |
| Total other income (expense) | 201,267 | -5,929,608.5* | -294,851 | -55,368 |
| Loss before income taxes | -17,553,762 | -22,113,387.75* | - | - |
| Deferred income tax provision | 231,309 | 56,517* | - | - |
| Net loss | -17,785,071 | -22,169,904.75* | -4,856,051 | -4,276,502 |
| Accrual of paid-in-kind dividends on series a non-voting convertible preferred stock | 1,725,225 | 402,552.75* | - | - |
| Net loss attributable to common stockholders | -19,510,296 | -22,572,457.5 | - | - |
| Basic EPS | -21.28 | -56.178 | -5.82 | -5.13 |
| Diluted EPS | -21.28 | -56.178 | -5.82 | -5.13 |
| Basic Average Shares | 916,968 | 401,802 | 833,683 | 833,654 |
| Diluted Average Shares | 916,968 | 401,802 | 833,683 | 833,654 |